Please use this identifier to cite or link to this item: https://hdl.handle.net/10316/111190
DC FieldValueLanguage
dc.contributor.authorSharifi, Esmaeel-
dc.contributor.authorYousefiasl, Satar-
dc.contributor.authorTrovato, Maria-
dc.contributor.authorSartorius, Rossella-
dc.contributor.authorEsmaeili, Yasaman-
dc.contributor.authorGoodarzi, Hamid-
dc.contributor.authorGhomi, Matineh-
dc.contributor.authorBigham, Ashkan-
dc.contributor.authorMoghaddam, Farnaz Dabbagh-
dc.contributor.authorHeidarifard, Maryam-
dc.contributor.authorPourmotabed, Samiramis-
dc.contributor.authorNazarzadeh Zare, Ehsan-
dc.contributor.authorPaiva-Santos, Ana Cláudia-
dc.contributor.authorRabiee, Navid-
dc.contributor.authorWang, Xiangdong-
dc.contributor.authorTay, Franklin R-
dc.date.accessioned2024-01-04T12:05:27Z-
dc.date.available2024-01-04T12:05:27Z-
dc.date.issued2023-06-21-
dc.identifier.issn1477-3155pt
dc.identifier.urihttps://hdl.handle.net/10316/111190-
dc.description.abstractViruses are a major cause of mortality and socio-economic downfall despite the plethora of biopharmaceuticals designed for their eradication. Conventional antiviral therapies are often ineffective. Live-attenuated vaccines can pose a safety risk due to the possibility of pathogen reversion, whereas inactivated viral vaccines and subunit vaccines do not generate robust and sustained immune responses. Recent studies have demonstrated the potential of strategies that combine nanotechnology concepts with the diagnosis, prevention, and treatment of viral infectious diseases. The present review provides a comprehensive introduction to the different strains of viruses involved in respiratory diseases and presents an overview of recent advances in the diagnosis and treatment of viral infections based on nanotechnology concepts and applications. Discussions in diagnostic/therapeutic nanotechnology-based approaches will be focused on H1N1 influenza, respiratory syncytial virus, human parainfluenza virus type 3 infections, as well as COVID-19 infections caused by the SARS-CoV-2 virus Delta variant and new emerging Omicron variant.pt
dc.language.isoengpt
dc.publisherSpringer Naturept
dc.rightsopenAccesspt
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt
dc.subjectAntiviral therapypt
dc.subjectDelta variantpt
dc.subjectOmicron variantpt
dc.subjectSARS-CoV-2pt
dc.subjectViral infectionspt
dc.subject.meshHumanspt
dc.subject.meshSARS-CoV-2pt
dc.subject.meshCOVID-19 Testingpt
dc.subject.meshInfluenza A Virus, H1N1 Subtypept
dc.subject.meshCOVID-19pt
dc.subject.meshVirus Diseasespt
dc.subject.meshPneumoniapt
dc.subject.meshNanostructurespt
dc.titleNanostructures for prevention, diagnosis, and treatment of viral respiratory infections: from influenza virus to SARS-CoV-2 variantspt
dc.typearticle-
degois.publication.firstPage199pt
degois.publication.issue1pt
degois.publication.titleJournal of Nanobiotechnologypt
dc.peerreviewedyespt
dc.identifier.doi10.1186/s12951-023-01938-8pt
degois.publication.volume21pt
dc.date.embargo2023-06-21*
uc.date.periodoEmbargo0pt
item.cerifentitytypePublications-
item.languageiso639-1en-
item.fulltextCom Texto completo-
item.grantfulltextopen-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.openairetypearticle-
crisitem.author.orcid0000-0003-2710-6000-
Appears in Collections:FFUC- Artigos em Revistas Internacionais
Show simple item record

Page view(s)

22
checked on May 22, 2024

Download(s)

23
checked on May 22, 2024

Google ScholarTM

Check

Altmetric

Altmetric


This item is licensed under a Creative Commons License Creative Commons